Depression and use of antidepressants in the critical patient;Depresión y uso de antidepresivos en el paciente crítico

Medicina Intensiva

Volumn 32, Issue SUPPL. 1, 2008, Pages 92-99

  Sandiumenge, A ^a   Torrado, H ^b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antidepressant; Critically ill patient; Depression; Emotional disturbances; Intensive care unit

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LOCAL ANESTHETIC AGENT; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PETHIDINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGRANULOCYTOSIS; ANOREXIA; BLEEDING; CARDIOTOXICITY; CONGENITAL MALFORMATION; CONVULSION; CRITICALLY ILL PATIENT; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; ENURESIS; HOSPITAL ADMISSION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; INTENSIVE CARE UNIT; NEUTROPENIA; PRESCRIPTION; PRIAPISM; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL RATING SCALE; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ANTIDEPRESSIVE AGENTS; CRITICAL ILLNESS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; INTENSIVE CARE UNITS;

EID: 45749129500     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. msc.es/Diseno/sns/sns_sistemas_informacion.htm
2. Murray CJ, López AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease sudy. Lancet. 1997;349:1498-1504.
3. Murray CJ, López AD. The global burden of disease. Geneva, Switzerland: World Health Organization; 1996.
4. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden L, Cuffe M, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Int Med. 2001;161:1849-56.
5. Van Den Brink RH, Van Melle JP, Honig A, Schene A, Crinjs HJGM, Lambert FPG, et al; on belhaf of the MIND-IT investigators. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: Rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). Am Heart J. 2002;144:219-25.
6. Misra S, Ganzini L. Delirium, depression and anxiety. Crit Care Clin. 2003;19:771-87.
7. Sanders K, Cassem E. Psychiatric Complications in the Critically ill Cardiac Patient. Tex Heart Inst J. 1993;20:180-7.
8. Jackson J, Hart RP, Gordon S, Shintani A, Truman B, May L, et al. Six month neuropsychological outcomes of medical intensive care unit patients. Crit Care Med. 2003;31:1226-34.
9. Hopkins R, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme JF Jr. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005;171:340-7.
10. Burg MM, Benedetto MC, Rosenberg R, Soufer R. Presurgical depression predicts medical morbidity 6 months after coronary artery bypass graft surgery. Psychosom Med. 2003;65:111-8.
11. Burg MM, Benedetto C, Soufer R. Depressive symptoms and mortality two years after coronary artery bypass graft surgery (CABG) in men. Psychosom Med. 2003;65:508-10.
12. Borowicz L, Royall R, Grega M, Selnes O, Lyketsos C, Mc Khann G. Depression and cardiac morbidity 5 years after coronary artery bypass surgery. Psychosomatics. 2002;43:464-71.
13. Zipdel S, Schneider A, Wild B, Löwe B, Jünger J, Haass M, et al. Effect of depressive symptoms on survival after heart transplantation. Psychosom Med. 2002;64:740-7.
14. Depression Guideline Panel. Clinical practice guideline, number 5. Depression in primary care: vol 1. Detection and diagnosis. AHCPR Pub. No 93-0551. Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1993.
15. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heartrate variability, and acute myocardial infarction. Circulation. 2001;104:2024-8.
16. Diagnostic and Statistical Manual of Mental Disorders 4 th ed: DSM IV. Washington DC: Americam Psychiatric Association; 1994.
17. Rincón HG, Granados M, Unutzer J, Gómez M, Duran R, Badiel M, et al. Prevalence, detection and treatment of anxiety, depression and delirium in the adult critical care unit. Psychosomatics. 2001;42:391-406.
18. Koenig H, George L, Peterson B, Pieper C. Depression in medically ill hospitalized older adults: prevalence, characteristics and course of symptoms according to six diagnostic schemes. Am J Psychiatry. 1997;154:1376-83.
19. Beck AT. Psychometric properties of the Beck Depression Inventory: twenty-five years later. Clin Psychol Rev. 1988;8:77-100.
20. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
21. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
22. Herbert AS, Lewis S, Mahendran R, Platt J, Bhattacharyya B. Screening for depression among acutely ill geriatric inpatients with short geriatric depression scale. Age and Ageing. 1997;26:217-21.
23. Gilbody S, House A, Sheldon T. Routinely administered questionnaires for depression and anxiety: Systematic review. Br Med J. 2001;322:406-9.
24. Walder B, Francioli D, Meyer JJ, Lançon M, Romand JA. Effects of guidelines implementation in a surgical intensive care unit to control nighttime light and noise levels. Walder B, Francioli D, Meyer JJ, Lançon M, Romand JA. Crit Care Med. 2000;28:2242-7.
25. Hewitt J. Psycho-affective disorder in intensive care units: a review. J Clin Nurs. 2002;11:575-84.
26. Chlan L: Effectiveness of a music therapy intervention on relaxation and anxiety for patients receiving ventilatory assistance. Heart Lung. 1998;27:169-76.
27. Richards KC. Effect of a back massage and relaxation intervention on sleep in critically ill patients. Am J Crit Care. 1998;7:288-99.
28. Treggiari-Venzi M, Borgeat A, Fuchs-Buder T, Gachoud P, Suter PM. Overnight sedation with midazolam or propofol in the ICU: Effects on sleep quality, anxiety and depression. Intensive Care Med. 1996;22:1186-90.
29. Kress JP, Gehlbach B, Lacy M, Pliskin N, Pohlman AS, Hall J. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med. 2003;168:1457.
30. Jones C, Skirrow P, Griffiths RD, Humphris GH, Ingleby S, Eddleston J, et al. Rehabilitation after critical illness: a randomized, controlled trial. Critical Care Med. 2003;31:2456-61.
31. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al.; Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106-16.
32. Travé Rodríguez AL, Reneses Sacristán A. Manejo de los fármacos en el tratamiento de la depresión. Información terapéutica del Sistema Nacional de Salud 2002; 26: no. 1.
33. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;175-89.
34. Roose SP, Laghrissi-Thode F, Kennedy JS, Craig Nelson J, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, Mc Cafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279:287-91.
35. Roose SP, Glassman AH, Attia E, Wooddring S, Giardina EG, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155:660-5.
36. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783-9.
37. Shapiro PA, Lesperance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial). Am Heart J. 1999;137:1100-6.
38. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger T, et al. Sertraline treatment of major depression in pacients with acute MI or unstable angina (the SADHART trial). JAMA. 2002;288:701-9.
39. Mc Farlane A, Kamath KV, Fallen EL, Malcolm V, Cherian F, Geoff N. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001;142:617-23.
40. Pollock Bg, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;2:137-40.
41. Carney RM, Blumenthal JA, Catellier D, Freedland KE, Berkman LF, Watkins LL, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol. 2003;92:1277-81.
42. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099-104.
43. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211-4.
44. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829-32.
45. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351-9.
46. Jorge RE, Robinson RG, Ardnt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003;160:1823-9.
47. Fruehwald S, Gatterbauer E, Rehak P, Baumhack U. Early fluoxetine treatment of post-stroke depression-a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347-51.
48. De Abajo FJ, García Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-9.
49. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br Med J. 1996;313:253-8.
50. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978-86.
51. Hypericum Depression Trial Study Group. Effect of hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807-14.
52. Gelenberg AJ, Shelton RC, Crits Christoph P, Keller MB, Dunner DL, Hirschfeld RM, et al. The effectivness of St John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. 2004;65:1114-9.
53. Boletín Informativo del Centro de Farmacovigilancia de la Comunidad de Madrid. Reacc Advers Medicam 2003;10.
54. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 2000;355:547-8.
55. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin pharmacol Ther. 1999;66:338-45.
56. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000;355:548-9.
57. Rothenhausler HB, Ehrentraut S, von Degenfeld G, Weis M, Tichy M, Kilger E, et al. Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. J Clin Psychiatry 2000;61:750-5.
58. Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005;65:1051-9.